Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …

Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

The therapeutic options for patients with noninvasive or invasive breast cancer are complex
and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include …

Breast cancer is the second leading cause of death for women worldwide. The
heterogeneity of this disease presents a big challenge in its therapeutic management …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …

Background The randomized, double-blind OlympiA trial compared 1 year of the oral poly
(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as …

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …

Background There is a high unmet need for treatment regimens that increase the chance of
long-term remission and possibly cure for women with newly diagnosed advanced ovarian …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …